This content is not available in your region

Novartis raises 2018 sales outlook as Entresto, Cosentyx accelerate

Access to the comments Comments
Novartis raises 2018 sales outlook as Entresto, Cosentyx accelerate
FILE PHOTO: The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland January 25, 2017. REUTERS/Arnd Wiegmann/File Photo   -   Copyright  Arnd Wiegmann(Reuters)
Text size Aa Aa

By John Miller

ZURICH (Reuters) – Swiss drugmaker Novartis <NOVN.S> raised its full-year sales outlook, citing growing revenue from its Cosentyx psoriasis and arthritis drug as well as the performance of its heart failure medicine Entresto, whose third-quarter sales more than doubled.

It also announced on Thursday the $2.1 billion (£1.6 billion) acquisition of U.S. biopharmaceutical company Endocyte <ECYT.O>.

Novartis now expects sales to grow in the mid-single-digit percentage range at constant currencies, up from its previous forecast of low-to-mid-single-digit percentage rates.

Operating profit was still seen rising in the mid-to-high-single-digit percentages.

Third-quarter core net income rose 2 percent to $3.1 billion, compared to the average analyst forecast of $3 billion in a Reuters poll.

Sales rose 3 percent to $12.78 billion, compared to the average forecast of $12.84 billion in the poll.

Novartis said it expected 2018 net sales at its innovative medicines division to grow at a mid-to-high-single digit rate, its Sandoz generics business to decline at a low-single-digit rate, and its Alcon eye care business to grow at a mid-single-digit pace.

(Reporting by John Miller; Editing by Michael Shields)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on for a limited time.